This clinical trial focuses on improving treatment for people with Type 1 diabetes. The study examines a new combination of two medications: insulin lispro (Lyumjev) and glucagon. Type 1 diabetes is a condition where the body cannot produce insulin, a hormone necessary for controlling blood sugar levels.
The purpose of this research is to determine if mixing a small amount of glucagon with insulin can help the body absorb insulin more quickly after injection under the skin. The study will use a specially prepared solution that combines Lyumjev (a fast-acting insulin) with glucagon (a hormone that normally increases blood sugar) in specific amounts.
During the study, participants will receive subcutaneous injections of this combined insulin-glucagon solution. The solution contains 50 nanograms of glucagon for each unit of insulin. The treatment period will last up to two days, during which researchers will monitor how quickly the insulin works and how it affects blood sugar levels. The maximum daily dose of insulin will be 20 units, while the maximum amount of glucagon will be 0.5 micrograms.



Norway